Anti-Rat IL-6

Product No.: I-170

[product_table name="All Top" skus="I-170"]

- -
- -
Target
IL-6
Product Type
Polyclonal Antibody
Alternate Names
Interleukin-6, BSF2, HPGF, HSF, IFNB2, MGI-2, HGF, B Cell Differentiation Factor [BCDF]
Applications
ICC
,
N
,
WB

- -
- -
Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Rat
Host Species
Goat
Immunogen
Purified Recombinant Rat IL-6 (>98%)
Endotoxin Level
<0.1 EU/µg as determined by the LAL method
Formulation
This antigen affinity purified polyclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco’s phosphate buffered saline (1X PBS) pH 7.2 – 7.3 containing 5.0% w/v trehalose with no calcium, magnesium, or preservatives present.
State of Matter
Lyophilized
Storage and Handling
The lyophilized antigen affinity purified polyclonal antibody can be stored desiccated at -20°C to -70°C for twelve months from date of receipt. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. No detectable loss of activity was observed after six months.
Country of Origin
USA
Shipping
Next Day Ambient
Applications and Recommended Usage?
Quality Tested by Leinco
Western Blot: Suitable for use at concentration of 1 µg/mL.
Additional Applications Reported In Literature ?
Neutralization: Measured by its ability to neutralize IL‑6-induced proliferation in the T1165.85.2.1 mouse plasmacytoma cell line. Nordan, R.P. and M. Potter (1986) Science 233:566. The Neutralization Dose (ND50) is typically 0.1-0.5 µg/mL in the presence of 0.6 ng/mL Recombinant Rat IL‑6.
Immunocytochemistry: Suitable for use at concentration of 5-15 µg/mL.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Rabbit Anti-Rat Interleukin-6 (IL-6) recognizes Rat IL-6. This antigen affinity purified polyclonal antibody was purified using a proprietary chromatographic technique that includes covalently immobilizing the antigen proteins or peptides to agarose based beads. This purification method enhances specificity, reduces nonspecific binding of extraneous IgG and provides you with the most reliable reagent available for your early discovery research.
Background
IL-6 is a pleotropic 26 kD protein that can act as both a pro-inflammatory cytokine and an anti-inflammatory myokine, a form of cytokine produced in muscle cells that participates in tissue regeneration and repair, maintenance of healthy bodily functioning, and homeostasis within the immune system. IL-6 plays a part in the immune, endocrine, nervous, and hematopoietic systems, in addition to bone metabolism, regulation of blood pressure and inflammation. Osteoblasts secrete IL-6 to stimulate osteoclast formation. Smooth muscle cells in the tunica media of many blood vessels also produce IL-6 as a pro-inflammatory cytokine. Furthermore, IL-6 is an important mediator of fever and of the acute phase response which is the body's rapid attempt to restore homeostasis after tissue injury, infection, neoplastic growth, or immunological disturbance. In addition, IL-6 can be released into circulation in response to various stimuli including PAMPs (pathogen-associated molecular patterns) and cortisol, a hormone produced by the human body under psychologically stressful conditions. In its role as an anti-inflammatory myokine, IL-6 precedes the appearance of other cytokines in the circulation, is notably elevated with exercise, and is mediated by both its inhibitory effects on TNF-α and IL-1, and activation of IL-1ra and IL-10. IL-6 signals through a cell-surface type I cytokine receptor complex formed by the binding of IL-6 to IL-6R, forming a binary complex, which in turn combines with GP130 to transduce extracellular signaling by the activation STAT3. Hence, it is thought that blocking the interaction between IL-6 and GP130 may have therapeutic potential via the inhibition of the IL-6/GP130/STAT3 signaling pathway. Moreover, IL-6 initiates the inflammatory and auto-immune processes in many diseases such as diabetes, atherosclerosis, depression, Alzheimer's disease, rheumatoid arthritis, cancer, and various others. Thus, there is an interest in the therapeutic potential of anti-IL-6 mAbs.

Antigen Details

PubMed
NCBI Gene Bank ID
Research Area
Other Molecules

References & Citations

1. Pederson, BK. et al. (2005) Exerc Sport Sci Rev 33: 114
2. Baier, M. et al. (1997) Proc Natl Acad Sci U S A. 94: 5273
ICC
N
General Western Blot Protocol
- -
- -
Products are for research use only. Not for use in diagnostic or therapeutic procedures.